Development of Antibody drug conjugate drug products

11:20 - 11:55

 

The CMC development of ADCs can be regarded as an extension of current MAb development strategies, and standard MAbs are further processed in order to attach cytotoxic payloads. This extension impacts resources and time required for process development (conjugation, formulation, and analytics), the complexity of these processes as well as the final product. The presentation shall provide insights into drug product development of ADCs at Novartis including:

Daniel Schweizer, DP Project Lead TD NBE’s, Novartis